Back to top

Genentech announces priority review for Enspryng

Genentech, a member of the Roche (RHHBY), announced that the FDA has accepted and granted priority review to a supplemental biologics license appli...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Roche Holding AG (RHHBY)

Rogers Corporation (ROG)

Roper Technologies, Inc. (ROP)